BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11362996)

  • 41. 3TC approval may revive AZT's appeal.
    Vazquez E
    Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical experience with saquinavir.
    Vella S
    AIDS; 1995 Dec; 9 Suppl 2():S21-S25. PubMed ID: 8775803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Boston, Galveston, Jackson County, Jefferson County, New York City, Portland--new saquinavir trial.
    AIDS Treat News; 1995 Sep; (no 231):6. PubMed ID: 11362872
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Why the old saquinavir (Invirase) may be bad for your health.
    Vazquez E
    Posit Aware; 1997; 8(4):28-31. PubMed ID: 11364485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protease inhibitor update: treatment combination strategies.
    Mascolini M
    AIDS Treat News; 1996 Jan; (no 239):3. PubMed ID: 11363085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
    Vazquez E
    Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lamivudine (3TC) approved for combination use with AZT.
    James JS
    AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Saquinavir with grapefruit juice.
    Posit Aware; 1996; 7(1):5. PubMed ID: 11363122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The combination of saquinavir and ddC ensures longer survival].
    Hoof T
    Dtsch Med Wochenschr; 1996 Sep; 121(37):A30. PubMed ID: 8925721
    [No Abstract]   [Full Text] [Related]  

  • 51. Protease inhibitors-at-a-glance.
    Notes Undergr; 1996 Apr; (no 32):4-5. PubMed ID: 11363449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nelfinavir - major trial results at retroviruses conference.
    AIDS Treat News; 1997 Feb; (No 265):3-4. PubMed ID: 11364240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Soft gel saquinavir has high exposure.
    AIDS Alert; 1997 Dec; 12(12):143-4. PubMed ID: 11364835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
    James JS
    AIDS Treat News; 1995 Dec; (no 237):3. PubMed ID: 11363075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fourth protease inhibitor hits the market.
    AIDS Alert; 1997 May; 12(5):59-60. PubMed ID: 11364224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nelfinavir (Viracept) approved: fourth protease inhibitor available.
    James JS
    AIDS Treat News; 1997 Mar; (No 267):1-2. PubMed ID: 11364249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FDA approves nelfinavir. Food and Drug Administration.
    GMHC Treat Issues; 1997 Mar; 11(3):8. PubMed ID: 11364277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stanford study of saquinavir reveals low toxicities.
    AIDS Patient Care; 1995 Dec; 9(6):304-5. PubMed ID: 11361442
    [No Abstract]   [Full Text] [Related]  

  • 60. Saquinavir (Roche protease inhibitor) at higher doses.
    AIDS Treat News; 1995 Sep; (no 231):5. PubMed ID: 11362870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.